Dr. Sara M. Tolaney breaks down key takeaways from the DESTINY-Breast09 trial that patients with HER2+ advanced or metastatic ...

Trastuzumab deruxtecan with pertuzumab significantly extended progression-free survival in HER2-positive advanced breast cancer, compared to standard THP therapy, according to DESTINY-Breast09 trial ...

Enhertu significantly improved overall survival and progression-free survival compared to Cyramza plus paclitaxel in HER2-positive metastatic GC/GEJ patients. The DESTINY-Gastric04 trial established ...

HER2 signaling can also promote cell survival and colonization at distant metastatic sites, establishing secondary tumors. HER2-positive tumors have different clinicopathological features and ...

DUBLIN, June 2, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced long-term data, including the first report of median overall survival (OS) from the Phase 2 trial ...

“Overall survival data are very immature at this ... Breast09 results “a pivotal advancement in the treatment of HER2-positive metastatic breast cancer that is both clinically and statisticall ...

Novartis Canada is pleased to announce that Health Canada has granted a Notice of Compliance (NOC) for KISQALI® (ribociclib ...

Researchers evaluated current treatment patterns and clinical outcomes for patients with HER2-positive metastatic breast cancer.